BioGaia AB: Year-end report January – December 2025

BioGaia reported FY2025 net sales of SEK 1,538.2m (organic +14%) and Q4 sales of SEK 440.6m (organic +32%), driven by Pediatrics and Adult Health growth and strong US performance. Full‑year operating profit fell 3% to SEK 412.5m (operating margin 27%) and adjusted operating profit declined 14%; profit after tax was SEK 332.8m and EPS fell to SEK 3.29 from 3.48. Year-end cash was SEK 801.3m (down from SEK 1,224.0m) and operating cash flow was negative SEK 406.6m, reflecting dividends of SEK 698.0m; the Board proposes a total dividend of SEK 4.00 per share (prior SEK 6.90). Management highlights product rollouts and two scientific publications (new patented strain and serotonin discovery), supporting medium‑term growth despite weaker cash flow and lower adjusted profitability.

Analysis

Market structure: BioGaia (Nasdaq Stockholm class B, “BIOG‑B”) is exhibiting a shift from partner‑led to direct distribution: direct markets now 10 and US sales reached SEK 316m (≈20% of 2025 revenue), creating faster organic growth (Q4 organic +32%) and higher brand pricing power in key retail channels. Product/IP wins (BG‑R46 patent, serotonin discovery) strengthen differentiation versus ingredient suppliers and commoditized probiotics, favoring branded consumer players over B2B ingredient vendors; expect BioGaia to capture 100–300bps of category share in prioritized markets over 12–24 months if launches scale as indicated.

Risk assessment: Key near‑term risks are inventory/order volatility (noted SEK ≈35m Q4 swing), FX translation (currency cut organic growth from 14% to 8% FY), and cash burn after SEK 698m dividends (cash down to SEK 801m). Tail risks include adverse regulatory rulings on health claims in EU/US or safety issues with a new strain—each could wipe out 20–40% of market cap in a stressed scenario; set hard impairment triggers (cash <SEK 500m or >60% dividend/FCF payout).

Trade implications: Favor a tactical constructive stance: BIOG‑B offers asymmetric upside as growth reaccelerates and margins re‑leverage (adjusted margin 27% vs 34% prior). Use defined‑risk option structures (9–12 month call spread) or a 2–3% long equity position with a 10–12% stop; pair long BIOG‑B vs short CHR.CO (Chr. Hansen) to isolate brand vs ingredient exposure, targeting 6–12 month horizon to capture market‑share gains and product rollouts (Germany/Austria Q1 2026).

Contrarian angles: Market may under‑value the long‑term IP monetization and consumer brand elasticity—consensus likely fixated on dividend cut (total SEK 4.00 vs 6.90 previous) and cash decline; this could underprice growth if new strains commercialize. Conversely, upside is capped if BioGaia maintains high dividend payouts that constrain R&D/M&A; re‑rate contingent on cash conversion—upside scenario: +15–25% EPS re‑rating if free cash flow turns positive and direct markets hit scale in 12–24 months.

Key Decisions for Investors

• Establish a 2–3% long position in BIOG‑B (Nasdaq Stockholm) within 5 trading days, target 12–18% upside in 6–12 months; set stop‑loss at 10–12% below entry and review if cash <SEK 500m or payout ratio >60% of FCF.
• Buy a 9–12 month BIOG‑B call spread (e.g., buy 25%‑OTM, sell 45%‑OTM) sized to represent ~1–1.5% portfolio exposure to capture product launch upside while capping premium outlay.
• Execute a pair trade: long BIOG‑B 1.0x vs short CHR.CO (Chr. Hansen) 0.8–1.0x for 6–12 months to isolate brand/retail execution upside; unwind if BIOG‑B underperforms by >15% relative to CHR over 3 months.
• Sell 3‑4 month covered calls on existing BIOG‑B exposure at ~10% OTM to harvest yield while maintaining upside if you hold shares; collect premium to offset dividend timing risk.
• Monitor three catalysts in next 60–120 days before scaling: March Q1 sales update/ordervolatility commentary, Germany/Austria launch KPIs (distribution points and reorder rates), and any regulatory guidance on probiotic health claims—add to position if reorder rates >30% month‑on‑month in new markets.